Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Wednesday, June 5, 2024 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11, 2024. The presentation will take place at 8:40 A.M. ET and will be available via a live webcast. The company is known for its focus on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), particularly its drug Rezdiffra (resmetirom), which aims to address key issues related to this liver disease. A replay of the webcast will be accessible after the event, further providing opportunities for investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a high-profile healthcare conference increases visibility.
  • Live presentation and replay available, enhancing investor engagement.
  • Focus on NASH, a condition with significant unmet medical need, showcases potential impact.

Full Press Release Details

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Tags

Frequently Asked Questions

When will Madrigal Pharmaceuticals present at the conference?

Madrigal will present at 8:40 A.M. ET on June 11, 2024.

Where can I watch the Madrigal conference presentation?

The presentation will be webcast live on Madrigal's website.

What is Madrigal Pharmaceuticals focused on developing?

Madrigal is focused on therapies for nonalcoholic steatohepatitis (NASH).

What is Rezdiffra designed to treat?

Rezdiffra (resmetirom) is designed to target key causes of NASH.

How often is Rezdiffra taken?

Rezdiffra is a once-daily oral medication.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals Goldman Sachs healthcare NASH
Last updated: Jun 5, 2024